FDA and Regulation
The U.S. Food and Drug Administration decides which drugs may be sold, how foods and dietary supplements may be labelled, which additives are allowed, and how new treatments are tested. Its notices, rules and actions shape what reaches the shelf and the clinic.
This section reports those actions on foods, supplements, remedies and plant medicines from the primary documents — the FDA announcement, the Federal Register notice and its docket — stating what each one does, what it asks, what it does not do, and the dates that matter. Each page links the related topic pages elsewhere on the site.
FDA Actions (11)
In date order, oldest first. The stars rate each action's legal weight: ★★★★★ a final action that changes what is sold or labelled nationwide; ★★★★ a proposed rule or order, or a final action of narrower reach; ★★★ a formal safety review or a final guidance; ★★ a request for information or a public meeting.
FDA Food Dye Actions in 2026
2026: the FDA revoked Orange B, proposed revoking Citrus Red No. 2, approved beetroot red and widened spirulina extract, and relaxed “no artificial colors” claims.
Read the full action →FDA Safety Reassessments of BHA, BHT and ADA (2026)
2026: the FDA opened post-market safety reassessments of the preservatives BHA and BHT and the dough conditioner azodicarbonamide, and finalized its chemical-review framework.
Read the full action →FDA Approves New Menopausal Hormone Therapy Labels (2026)
February 2026: the FDA approved the first six hormone therapy labels without boxed-warning statements on heart disease, breast cancer and probable dementia.
Read the full action →FDA Public Meeting on What Counts as a Dietary Ingredient (2026)
March 2026: the FDA asked for public input on how the “dietary substance” category applies to fermentation-made, cell-cultured and recombinant supplement ingredients.
Read the full action →FDA Review of Compounded Peptides Including BPC-157 (2026)
2026: BPC-157 and other peptides left the FDA’s significant-safety-risk category; in July the FDA proposed not listing any of the seven it took to its advisory committee.
Read the full action →FDA Proposal on Compounded Semaglutide and Tirzepatide (2026)
April 2026: the FDA proposed keeping semaglutide, tirzepatide and liraglutide off the list outsourcing facilities may compound from bulk ingredients, finding no clinical need.
Read the full action →7-OH Kratom Products: The 2026 Scheduling Steps
July 2026: the DEA moved to place concentrated 7-OH in Schedule I, with HHS and FDA support; natural kratom leaf is not the target.
Read the full action →FDA Final Guidance on Psychedelic Drug Trials (2026)
July 2026: the FDA finalized its guidance on designing clinical trials of psychedelic drugs and held a public hearing on possible future therapeutic use.
Read the full action →FDA Proposal to Make GRAS Notices Mandatory (2026)
August 2026: the FDA proposes requiring companies to notify it whenever they conclude a food ingredient is GRAS; comments close December 9, 2026.
Read the full action →FDA Request for Input on Botanical Drugs (2026)
September 2026: the FDA asked for public input on obstacles to developing plant-based prescription drugs, from quality standards to study design; comments close November 3.
Read the full action →FDA Ibogaine Research Notice (2026)
October 2026: the FDA asks for public comment on how early clinical trials of ibogaine should be designed (comments through November 20, 2026).
Read the full action →Earlier Years (2)
FDA Actions in 2024
Twenty major FDA actions of 2024, from the BVO revocation and the “healthy” label rule to the MDMA decision, the tirzepatide shortage and lead in cinnamon, in date order with importance stars.
See all 20 actions →FDA Actions in 2025
Twenty major FDA actions of 2025, from the Red No. 3 revocation and lead limits in baby food to opioid labels, NMN and the dye phase-out, in date order with importance stars.
See all 20 actions →